Zhijie Xu Selected Research

COVID-19

11/2021	Pre-hospital, in-hospital and post-hospital factors associated with sleep quality among COVID-19 survivors 6 months after hospital discharge: cross-sectional survey in five cities in China.
1/2021	SARS-CoV-2 Gastrointestinal Infection Prolongs the Time to Recover From COVID-19.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Zhijie Xu Research Topics

Disease

95	Neoplasms (Cancer) 04/2024 - 11/2013
15	Carcinogenesis 04/2024 - 01/2017
15	Glioma (Gliomas) 03/2024 - 02/2016
11	Lung Neoplasms (Lung Cancer) 11/2022 - 01/2017
9	Urinary Bladder Neoplasms (Bladder Cancer) 04/2024 - 01/2018
8	Ovarian Neoplasms (Ovarian Cancer) 03/2024 - 01/2021
8	Nasopharyngeal Carcinoma 07/2019 - 01/2013
7	Glioblastoma (Glioblastoma Multiforme) 03/2024 - 01/2017
7	Neoplasm Metastasis (Metastasis) 02/2024 - 03/2015
7	Hepatocellular Carcinoma (Hepatoma) 12/2023 - 01/2021
5	Inflammation (Inflammations) 12/2024 - 01/2017
5	Renal Cell Carcinoma (Grawitz Tumor) 12/2023 - 01/2022
5	Carcinoma (Carcinomatosis) 04/2023 - 01/2018
5	Adenocarcinoma of Lung 03/2023 - 01/2019
5	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2022 - 07/2019
4	Breast Neoplasms (Breast Cancer) 01/2023 - 04/2019
3	Liver Neoplasms (Liver Cancer) 01/2023 - 01/2022
3	Colorectal Neoplasms (Colorectal Cancer) 01/2022 - 11/2015
3	Colonic Neoplasms (Colon Cancer) 01/2021 - 11/2015
3	Infections 01/2021 - 01/2016
3	Reperfusion Injury 09/2019 - 01/2016
2	Triple Negative Breast Neoplasms 12/2024 - 01/2023
2	Bites and Stings (Sting) 01/2024 - 01/2022
2	Non-alcoholic Fatty Liver Disease 11/2023 - 01/2021
2	COVID-19 11/2021 - 01/2021
1	Pathologic Processes 04/2024
1	Digestive System Neoplasms (Cancer of the Digestive System) 01/2024
1	Ischemic Stroke 01/2024
1	Heart Failure 01/2024
1	Hypertension (High Blood Pressure) 01/2024
1	Coronary Artery Disease (Coronary Atherosclerosis) 01/2024
1	Genetic Predisposition to Disease (Genetic Predisposition) 01/2024

Drug/Important Bio-Agent (IBA)

33	Biomarkers (Surrogate Marker)IBA 12/2023 - 06/2015
26	Proteins (Proteins, Gene)FDA Link 03/2024 - 01/2018
12	RNA (Ribonucleic Acid)IBA 11/2023 - 01/2017
9	Temozolomide (Temodar)FDA LinkGeneric 03/2024 - 02/2016
9	Long Noncoding RNAIBA 12/2022 - 01/2017
7	EnzymesIBA 02/2023 - 01/2016
6	Cisplatin (Platino)FDA LinkGeneric 12/2024 - 01/2017
6	MicroRNAs (MicroRNA)IBA 01/2021 - 03/2015
5	6-methyladenineIBA 04/2024 - 12/2020
5	Indicators and Reagents (Reagents)IBA 04/2023 - 01/2021
5	DNA (Deoxyribonucleic Acid)IBA 01/2022 - 01/2016
5	Catalytic DNA (Deoxyribozyme)IBA 03/2015 - 01/2013
4	N-methyladenosineIBA 04/2024 - 12/2020
4	Messenger RNA (mRNA)IBA 03/2024 - 01/2022
4	Reactive Oxygen Species (Oxygen Radicals)IBA 03/2024 - 10/2016
4	Phosphotransferases (Kinase)IBA 03/2024 - 01/2019
3	AntigensIBA 01/2024 - 11/2020
3	CytokinesIBA 01/2024 - 01/2016
3	Circular RNAIBA 01/2023 - 01/2018
3	Therapeutic UsesIBA 01/2022 - 11/2020
3	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 01/2022 - 01/2019
3	DioxygenasesIBA 01/2022 - 01/2021
3	Tyrosine (L-Tyrosine)FDA Link 11/2021 - 09/2019
3	Adenosine DeaminaseIBA 01/2021 - 01/2019
3	AcidsIBA 09/2014 - 05/2013
2	tabersonineIBA 12/2024 - 02/2024
2	NF-kappa B (NF-kB)IBA 03/2024 - 01/2016
2	olaparibIBA 03/2024 - 02/2024
2	Immune Checkpoint InhibitorsIBA 01/2024 - 02/2023
2	Peptides (Polypeptides)IBA 01/2024 - 11/2020
2	Contrast MediaIBA 09/2023 - 11/2013
2	MetalsIBA 06/2023 - 01/2021
2	LigandsIBA 01/2023 - 01/2019
2	MethyltransferasesIBA 01/2023 - 10/2019
2	InflammasomesIBA 01/2023 - 01/2022
2	purineIBA 10/2022 - 04/2019
2	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2022 - 11/2013
2	Complement System Proteins (Complement)IBA 01/2022 - 01/2018
2	Protein Kinases (Protein Kinase)IBA 01/2022 - 01/2021
2	Protein Serine-Threonine Kinases (Protein-Serine-Threonine Kinase)IBA 01/2022 - 01/2022
2	Serine (L-Serine)FDA Link 11/2021 - 01/2021
2	Adenosine (Adenocard)FDA LinkGeneric 01/2021 - 01/2019
2	immune RNA (I-RNA)IBA 01/2021 - 01/2019
2	Inosine FDA Link 01/2021 - 01/2019
2	CarcinogensIBA 01/2020 - 11/2018
2	3,8-dihydroxy-6H-dibenzo(b,d)pyran-6-oneIBA 09/2019 - 07/2019
2	DiterpenesIBA 07/2019 - 11/2015
2	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 01/2019 - 01/2016
2	aloperineIBA 01/2019 - 01/2017
2	CateninsIBA 01/2019 - 01/2017
2	Radiation-Sensitizing AgentsIBA 11/2018 - 01/2017
2	Nuclear Respiratory Factor 1IBA 06/2015 - 10/2013
1	Aurora Kinase AIBA 12/2024
1	Environmental Pollutants (Pollutants, Environmental)IBA 04/2024
1	Caspase 8 (Caspase-8)IBA 03/2024
1	Poly(ADP-ribose) Polymerases (Poly ADP Ribose Polymerase)IBA 03/2024
1	Poly Adenosine Diphosphate RiboseIBA 03/2024
1	Inositol 1,4,5-TrisphosphateIBA 03/2024
1	ChemokinesIBA 01/2024
1	Antineoplastic Agents (Antineoplastics)IBA 01/2024
1	NexusIBA 01/2024
1	IntegrinsIBA 12/2023
1	Small Cytoplasmic RNAIBA 11/2023

Therapy/Procedure

28	Therapeutics 01/2024 - 11/2015
16	Immunotherapy 03/2024 - 10/2019
11	Drug Therapy (Chemotherapy) 09/2023 - 11/2015
7	Radiotherapy 09/2023 - 06/2015
2	Length of Stay 01/2023 - 11/2021